Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)



Status:Recruiting
Conditions:Colitis, Colitis, Gastrointestinal, Crohns Disease
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:2 - 17
Updated:10/11/2018
Start Date:July 30, 2018
End Date:June 14, 2025
Contact:Takeda Study Registration Call Center
Email:medicalinformation@tpna.com
Phone:+1-877-825-3327

Use our guide to learn which trials are right for you!

A Phase 2b, Extension Study to Determine the Long-term Safety of Vedolizumab IV in Pediatric Subjects With Ulcerative Colitis or Crohn's Disease

The purpose of this study is to determine the safety profile of long-term vedolizumab IV
treatment in pediatric participants with UC or CD.

The drug being tested in this study is called Vedolizumab. Vedolizumab is being tested to
treat pediatric participants who have moderately to severely active UC or CD.

This study will look at the long-term safety profile in participants who take vedolizumab IV.
Participants will be randomly assigned (by chance, like flipping a coin) which will remain
undisclosed to the participant and investigator during this double blind study (up to Week
40) maintaining the dose at study entry and escalating the dose at disease worsening.

The dosing regimen selected for the long-term study is intended to maintain clinical response
at the lowest possible exposure.

At the discretion of the investigator, participants receiving the low dose (150 or 100 mg) of
vedolizumab IV may be escalated to the high dose (300 or 200 mg) if the participants
demonstrate disease worsening at 2 consecutive visits (scheduled or unscheduled).

Participants who experience continued disease worsening during the study despite being
administered vedolizumab 300 or 200 mg every 8 weeks (Q8W) will be discontinued from the
study.

Study duration is expected to be up to 5 years, depending on the enrollment rate in the
previous randomized double blind study (MLN0002-2003).

Inclusion Criteria:

1. Is male or female with Ulcerative Colitis or Crohn's Disease and was between 2 to 17
years, inclusive, at the time of randomization for Study MLN0002-2003.

(Note: A participant remains eligible to participate in this study after they reach 18
years of age if they continue to meet the inclusion criteria and do not meet any
exclusion criteria.)

2. Has completed Study MLN0002-2003 and, at Week 22, achieved clinical response as
defined by a reduction of partial Mayo score of >= 2 points and >= 25% from Baseline,
or a reduction of the paediatric ulcerative colitis activity index (PUCAI) of >= 20
points from baseline for participants with UC; or a reduction of the CDAI as defined
by a >= 70-point decrease from Baseline or a decrease of pediatric crohn's disease
activity index (PCDAI) of >= 15 points for participants with CD.

3. May be receiving a therapeutic dose of the following drugs:

- Oral 5-aminosalicylic acid (5-ASA) compounds.

- Oral corticosteroid therapy (prednisone or equivalent steroid at a dose less than
or equal to [<=] 50 milligram per day [mg/day], budesonide at a dose <= 9
mg/day).

- Topical (rectal) treatment with 5-ASAs or corticosteroids.

- Probiotics (example, Saccharomyces boulardii).

- Antidiarrheals (example, loperamide, diphenoxylate with atropine) for control of
chronic diarrhea.

- Antibiotics used for the treatment of CD (i.e., ciprofloxacin, metronidazole).

- Azathioprine (AZA) or 6-mercaptopurine (6-MP) or methotrexate (MTX), provided the
participant was receiving this medication during prior participation in
MLN0002-2003.

4. The participant's vaccinations are up to date as per inclusion criteria number 10 in
MLN0002-2003.

Exclusion Criteria:

1. Is female and is lactating or pregnant.

2. Has hypersensitivity or allergies to vedolizumab or any of its excipients.

3. Has withdrawn from Study MLN0002-2003.

4. Has developed any new unstable or uncontrolled cardiovascular, heart failure moderate
to severe (New York Class Association III or IV), pulmonary, hepatic, renal,
gastrointestinal (GI), genitourinary, hematological, coagulation, immunological,
endocrine/metabolic, neurological, or other medical disorder that, in the opinion of
the investigator, would confound the study results or compromise participant safety.

5. Has a positive progressive multifocal leukoencephalopathy (PML) subjective symptom
checklist prior to the administration of the first dose of study drug.

6. Currently requires major surgical intervention for ulcerative colitis (UC) or CD
(example, bowel resection), or is anticipated to require major surgical intervention
for UC or CD during the study.

7. Has other serious comorbidities that will limit his or her ability to complete the
study.
We found this trial at
18
sites
171 Ashley Avenue
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
?
mi
from
Charleston, SC
Click here to add this to my saved trials
282 Washington St
Hartford, Connecticut 06106
(860) 545-9000
Connecticut Children's Medical Center Connecticut Children’s Medical Center is a nationally recognized, 187-bed not-for-profit children’s...
?
mi
from
Hartford, CT
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
1 Gustave L Levy Pl # 271
New York, New York 10029
 (212) 241-6500
Mount Sinai Med Ctr Founded in 1852, The Mount Sinai Hospital is a 1,171-bed, tertiary-care...
?
mi
from
New York, NY
Click here to add this to my saved trials
4401 Penn Avenue
Pittsburgh, Pennsylvania 15224
412-692-5325
Children's Hospital of Pittsburgh of UPMC UPMC is one of the leading nonprofit health systems...
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
300 Longwood Ave
Boston, Massachusetts 02115
(617) 355-6000
Boston Children's Hospital Boston Children's Hospital is a 395-bed comprehensive center for pediatric health care....
?
mi
from
Boston, MA
Click here to add this to my saved trials
225 E Chicago Ave
Chicago, Illinois 60611
(312) 227-4000
Ann & Robert H. Lurie Children's Hospital of Chicago Ann & Robert H. Lurie Children
?
mi
from
Chicago, IL
Click here to add this to my saved trials
1935 Medical District Dr
Dallas, Texas 75235
(214) 456-7000
Children's Medical Center of Dallas Children's Medical Center is private, not-for-profit, and is the fifth-largest...
?
mi
from
Dallas, TX
Click here to add this to my saved trials
6621 Fannin St
Houston, Texas 77030
(832) 824-1000
Texas Children's Hospital Texas Children's Hospital, located in Houston, Texas, is a not-for-profit organization whose...
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Lake Success, New York 11042
?
mi
from
Lake Success, NY
Click here to add this to my saved trials
Leuven, Flemish Brabant
?
mi
from
Leuven,
Click here to add this to my saved trials
200 First Street SW
Rochester, Minnesota 55905
507-284-2511
Mayo Clinic Rochester Mayo Clinic is a nonprofit worldwide leader in medical care, research and...
?
mi
from
Rochester, MN
Click here to add this to my saved trials
San Francisco, California 94143
?
mi
from
San Francisco, CA
Click here to add this to my saved trials
4800 Sand Point Way NE
Seattle, Washington 98105
(206) 987-2000
Seattle Children's Hospital Seattle Children’s Hospital specializes in meeting the unique physical, emotional and developmental...
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Wilmington, DE
Click here to add this to my saved trials